Pick · 10.0% · mega · Finance · last 343.06
Entry 335.00–340.00 · Stop 325.00 · Target 370.00
Thesis (long, position, conviction 64)
Bull: JPM delivered exceptional Q2 2026 results: revenue up 27.7% YoY to $57.3B, net income up 41.1% to $21.2B, and diluted EPS of $7.70 vs $5.24 a year ago (F-JPM-1, F-JPM-2, F-JPM-3). Profitability metrics are best-in-class for a mega-cap bank — 24% ROE, 29% ROTCE, and a 110% LCR (F-JPM-6) — while credit provisions actually fell 11.7% YoY, indicating benign credit quality even as the loan book grows (F-JPM-5). Six-month revenue is up 18.8% YoY (F-JPM-4), and the company continues to shrink its share count (down 3.3% YoY, F-JPM-7), adding a buyback tailwind to EPS. Sell-side sentiment is uniformly constructive: 18 of 30 covering analysts rate it buy/strong buy with zero sells or holds-only skew and no sell ratings at all (F-JPM-11). The stock has pulled back 6.1% from its 52-week high (F-JPM-8) and sits with RSI-14 at 41.7 — neutral-to-oversold rather than stretched — while remaining comfortably above its 200-day moving average of $319.54 (F-JPM-9), suggesting the long-term uptrend is intact and this is a garden-variety pullback within it rather than a trend break. Q3 earnings on 2026-10-13 (F-JPM-12) is a near-term catalyst that could reignite momentum if the run of beats continues.
Bear: Momentum has clearly stalled: JPM is below both its 20-day and 50-day moving averages ($351.26 and $353.34, F-JPM-9), down 3.77% over the last month, and has underperformed the S&P 500 by 1.35 points over three months despite a positive 4.73% three-month return (F-JPM-10). This relative weakness in a mega-cap bank during a "neutral" macro regime warrants some caution — the market may be rotating away from banks or pricing in normalization from an unusually strong Q2 print (27.7% revenue growth is not a sustainable run-rate). A reported insider sale by EVP Robin Leopold on 2026-09-10 (F-JPM-13) is a minor negative signal, though unverified against the primary Form 4 filing. The Q3 EPS estimate of $5.8818 (F-JPM-12) implies a sequential deceleration from Q2's $7.70, and if actual results merely meet rather than beat this lowered bar, the stock could continue drifting toward the 200-day MA near $320 rather than reclaiming highs.
Valuation: The brief does not provide a P/E or explicit valuation multiple, so a precise cheap/expensive call isn't possible from this data alone. However, the profitability profile — 24% ROE, 29% ROTCE, falling credit costs, and shrinking share count — is exceptional for a bank of JPM's size, and historically commands a premium multiple. Trading 6% off all-time highs with fundamentals still accelerating (Q2 EPS +47% YoY) suggests the pullback is more technical/rotational than valuation-driven; the setup favors buying strength in fundamentals at a discounted price rather than chasing new highs.
Catalysts
2026-10-13: Q3 2026 earnings release; consensus EPS estimate of $5.8818, a test of whether the growth/beat streak continues after an exceptional Q2
undated: Technical reclaim of the 50-day ($353.34) and 20-day ($351.26) moving averages would confirm the pullback is over and momentum is turning back up
Facts
F-JPM-1: Revenue for the quarter ended 2026-06-30 was $57.347 billion, up 27.7% from $44.912 billion in the quarter ended 2025-06-30. (as of 2026-06-30)[E1048]source
F-JPM-2: Net income for the quarter ended 2026-06-30 was $21.155 billion, up 41.1% from $14.987 billion a year earlier. (as of 2026-06-30)[E1047, E1048]sourcesource
F-JPM-3: Diluted EPS for the quarter ended 2026-06-30 was $7.70, compared with $5.24 for the quarter ended 2025-06-30. (as of 2026-06-30)[E1047, E1048]sourcesource
F-JPM-4: Revenue for the six months ended 2026-06-30 was $107.183 billion, up 18.8% from $90.222 billion for the same period in 2025. (as of 2026-06-30)[E1048]source
F-JPM-5: The provision for credit losses in 2026 Q2 was $2.515 billion, down 11.7% from $2.849 billion in 2025 Q2. (as of 2026-06-30)[E1048]source
F-JPM-6: For 2026 Q2, JPMorgan reported return on common equity of 24%, return on tangible common equity of 29%, and an average firm liquidity coverage ratio of 110%. (as of 2026-06-30)[E1048]source
F-JPM-7: Common shares outstanding at 2026-06-30 were 2,658.2 million, versus 2,749.7 million at 2025-06-30, a decrease of about 3.3%. (as of 2026-06-30)[E1048]source
F-JPM-8: JPM closed at $343.06 on 2026-09-25, 6.1% below its 52-week closing high of $365.18. (as of 2026-09-25)[E996]
F-JPM-9: At the 2026-09-25 close of $343.06, the stock was below its 20-day and 50-day moving averages ($351.26 and $353.34) but above its 200-day moving average ($319.54); its RSI-14 was 41.69. (as of 2026-09-25)[E996]
F-JPM-10: JPM's three-month return through 2026-09-25 was 4.73%, while its three-month relative strength versus the S&P 500 was -1.35 percentage points. (as of 2026-09-25)[E996]
F-JPM-11: For September 2026, analyst recommendations in the pack were 3 strong buys, 15 buys, and 12 holds, with no sell or strong-sell recommendations. (as of 2026-09-01)[E1020]
F-JPM-12: The next earnings date listed was 2026-10-13, with an EPS estimate of $5.8818 for 2026 Q3. (as of 2026-09-25)[E1020]
F-JPM-13: MarketBeat reported that insider Robin Leopold sold 2,500 shares on 2026-09-10 at an average price of $352.81; this report was not independently verified against the Form 4 in this review. (as of 2026-09-23)[E1009]source
Critic
O2 (major): The permitted entry near $345 offers thin reward relative to the stated stop, just ahead of earnings while momentum remains weak. Accepted: Entry ceiling cut from $345 to $340, improving reward/risk to 2:1 while keeping JPM's size at 10%.
What would change the view
A close below $325 (near the 200-day MA) invalidates the pullback-in-uptrend thesis and would argue for exiting
Q3 EPS miss versus the $5.8818 estimate combined with cautious forward commentary on net interest income or credit costs
Independent Form 4 confirmation showing a pattern of material, recurring insider selling beyond the single reported Leopold transaction
Data quality
Quality score 100/100.
Gap: The quote block is timestamped 2026-09-27, after the pack's stated date of 2026-09-25; the quote was not used.
Gap: The news block includes items published 2026-09-26, after the pack's stated date of 2026-09-25; those items were not used.
Gap: The reported insider sale was not independently verified against the primary Form 4 filing.
Red flag: A third-party report described an insider sale by Robin Leopold; the transaction was not independently checked against its SEC Form 4 in this review (E1009).